PUBLISHER: IMARC | PRODUCT CODE: 1450991
PUBLISHER: IMARC | PRODUCT CODE: 1450991
The global isothermal nucleic acid amplification technology (INAAT) market size reached US$ 3.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.9 Billion by 2032, exhibiting a growth rate (CAGR) of 10.8% during 2024-2032.
The isothermal nucleic acid amplification technology (INAAT) is used in molecular biology and recombinant DNA technologies for detecting and identifying nucleic acids. It is commonly used to amplify nucleic acids at a constant temperature, thereby eliminating the need for thermocycler equipment. It is majorly utilized for RNA, DNA, cells, proteins, small molecules, and ions to ensure the rapid, sensitive and accurate diagnosis of genetic, inherited, and infectious diseases. It generates amplicons that are employed in producing versatile nucleic acid nanomaterials. Besides this, it assists in detecting various infectious diseases, such as (HIV), tuberculosis, influenza, hepatitis A and B, chlamydia, and gonorrhea (CT/NG). As a result, INAAT is gaining immense traction across the globe.
The ongoing development in INAAT for detecting coronavirus disease (COVID-19) represents one of the key factors positively influencing the market. In line with this, the increasing geriatric population globally and the rising prevalence of cancer and other chronic medical disorders, along with the escalating demand for efficient diagnosis and treatment alternatives, are contributing to the market growth. Apart from this, the adoption of loop-mediated isothermal amplification (LAMP) tests to amplify DNA and RNA and the identification of genetically modified organisms (GMOs) is catalyzing the demand for INAAT. Furthermore, the development of strand displacement amplification (SDA), single primer isothermal amplification (SPIA), and recombinase polymerase amplification (RPA) are acting as another growth-inducing factor. Moreover, increasing investments in research and development (R&D) activities by leading market players are projected to drive the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global isothermal nucleic acid amplification technology market report, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product, technology, application, and end-user.
Instruments
Reagents
Reagents hold the majority of the global isothermal nucleic acid amplification technology market share due to their increasing use in therapeutics.
Helicase-Dependent Amplification (HDA)
Nicking Enzyme Amplification Reaction (NEAR)
Loop-Mediated Isothermal Amplification (LAMP)
Strand Displacement Amplification (SDA)
Nucleic Acid Sequence-Based Amplification (NASBA)
Transcription Mediated Amplification (TMA)
Single Primer Isothermal Amplification (SPIA)
Others
TMA accounts for the majority of the total market share as it allows a clinical laboratory to perform nucleic acid test (NAT) assays for blood screening with fewer steps and less processing time.
Infectious Disease Diagnosis
Hepatitis
CT/NG
HIV
Influenza
Others
Blood Screening
Others
Infectious disease diagnosis currently dominates the market due to the rising prevalence of infectious diseases across the globe.
Hospitals
Diagnostic Laboratories
Research Laboratories
Others
Hospitals presently dominate the market due to the increasing number of hospitals and significant development in the healthcare industry.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market due to the shifting consumer preference for INAAT testing over traditional diagnostic procedures.
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Some of these players are Abbott Laboratories, bioMerieux SA, Becton, Dickinson and Company, Eiken Chemical Co. Ltd., Hologic Inc., Meridian Bioscience Inc., OptiGene Limited, Thermo Fisher Scientific Inc., Tecan Trading AG, and Ustar Biotechnologies Ltd.